AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15300958 — intervention group
Group type: EXPERIMENTAL
Intervention: clopidogrel/ASA combination
Number of subjects: 12562
Study 15300958 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 12562
Study 11395702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-titanium alloys
Number of subjects: 0
Study 9737514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junction ablation and VVIR pacemaker (Abl+Pm)
Number of subjects: 66
Study 9737514 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (drug)
Number of subjects: 66
Study 9737514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 7943694 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/oxygen/nitrous oxide
Number of subjects: 20
Study 7943694 — intervention group
Group type: COMPARATOR
Intervention: Enflurane/oxygen/nitrous oxide
Number of subjects: 20
Study 3361324 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin subcutaneously three times daily (doses adjusted based on APTT)
Number of subjects: 102
Study 3361324 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus 0.5 mg dihydroergotamine twice daily (fixed dose of 5,000 IU heparin)
Number of subjects: 102
Study 30698114 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from escitalopram to nortriptyline (n = 36)
Number of subjects: 811
Study 30698114 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from nortriptyline to escitalopram (n = 72)
Number of subjects: 811
Study 30419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban (35-42 days)
Number of subjects: 7513
Study 30419597 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (10 ± 4 days)
Number of subjects: 7513
Study 30419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic DVT
Number of subjects: 7513
Study 30419597 — intervention group
Group type: COMPARATOR
Intervention: No DVT
Number of subjects: 7513
Study 27169641 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plans
Number of subjects: 400
Study 27169641 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping plans
Number of subjects: 400
Study 25262178 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + DM60 (60 mg/day)
Number of subjects: 309
Study 25262178 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA + DM30 (30 mg/day)
Number of subjects: 309
Study 25262178 — intervention group
Group type: COMPARATOR
Intervention: VPA + Placebo
Number of subjects: 309
Study 22931457 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating knowledge assessment through focus group interviews
Number of subjects: 103
Study 22931457 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions on barriers to healthy eating
Number of subjects: 103
Study 22931457 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection and analysis
Number of subjects: 103
Study 20212496 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 0.5 mg
Number of subjects: 417
Study 20212496 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 1 mg
Number of subjects: 417
Study 20212496 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 417
Study 20212496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 18069576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 5569
Study 18069576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5569
Study 16473748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical wheatgrass cream applied twice daily for 6 weeks
Number of subjects: 80
Study 16473748 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 6 weeks
Number of subjects: 80
Study 12395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specific types not mentioned)
Number of subjects: 0
Study 12395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative meta-analysis
Number of subjects: 0
Study 12395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of original data
Number of subjects: 0
Study 12395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods
Number of subjects: 0
Study 9452324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0
Study 9452324 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study 7842184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 12
Study 7842184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7842184 — intervention group
Group type: COMPARATOR
Intervention: Nasal occlusion
Number of subjects: 12
Study 2270546 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3% age oily solution)
Number of subjects: 0
Study 2270546 — intervention group
Group type: COMPARATOR
Intervention: Chlorphenol‐camphor‐menthol‐solution (ChKM) with procain on gauze strip
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment of levamisole (150 mg per day)
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment of levamisole (3 days per week, 150 mg)
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly treatment of levamisole (150 mg one day per week)
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular control of white blood cell counts 10 hours after intake of levamisole
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of levamisole in RA
Number of subjects: 0
Study 366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed treatment scheme of one single weekly dose of 150 mg
Number of subjects: 0
Study 30784667 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAPT) in non-high bleeding risk (HBR) patients
Number of subjects: 3118
Study 30784667 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAPT)
Number of subjects: 3118
Study 30784667 — intervention group
Group type: COMPARATOR
Intervention: Short-term dual antiplatelet therapy (DAPT)
Number of subjects: 3118
Study 28242304 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient education (12-hour training manual)
Number of subjects: 315
Study 26452168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with window open (average CO2 level 660 ppm)
Number of subjects: 30
Study 26452168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with inaudible fan disabled (average CO2 level 2395 ppm)
Number of subjects: 30
Study 26452168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedroom ventilation with inaudible fan operated (average CO2 level 835 ppm)
Number of subjects: 30
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication optimization at discharge (ACEI or ARB, β-blocker, MRA, diuretics)
Number of subjects: 1853
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific treatment procedures beyond pharmacotherapy
Number of subjects: 1853
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality and rehospitalization rates after 1 year
Number of subjects: 1853
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class status after 1 year
Number of subjects: 1853
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: General health status improvement after 1 year
Number of subjects: 1853
Study 25052361 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence after 1 year
Number of subjects: 1853
Study 22399699 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus exercise counseling
Number of subjects: 606
Study 22399699 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 606
Study 19631844 — intervention group
Group type: EXPERIMENTAL
Intervention: Various restorative treatments
Number of subjects: 0
Study 17049818 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (50 mg/14 days)
Number of subjects: 0
Study 17049818 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 0
Study 16316360 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 20
Study 16316360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16409880 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus oral nutritional supplements (360 ml of 1.5 kcal/ml, 20 g of protein per day) until hospital discharge
Number of subjects: 5033
Study 16409880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tube feeding
Number of subjects: 5033
Study 16409880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral tube feeding via PEG
Number of subjects: 5033
Study 16409880 — intervention group
Group type: COMPARATOR
Intervention: Enteral tube feeding via NG
Number of subjects: 5033
Study 10826395 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I (delapril)
Number of subjects: 1748
Study 10826395 — intervention group
Group type: COMPARATOR
Intervention: Ca‐antagonist (manidipine)
Number of subjects: 1748
Study 8651166 — intervention group
Group type: EXPERIMENTAL
Intervention: Rennie Liquid
Number of subjects: 12
Study 8651166 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox Liquid
Number of subjects: 12
Study 8651166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1813613 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (dopamine agonist)
Number of subjects: 0
Study 1813613 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (tricyclic antidepressant)
Number of subjects: 0
Study 1813613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6689226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin from the same lot number (Group I)
Number of subjects: 20
Study 6689226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin from different lot numbers (Group II)
Number of subjects: 20
Study 30132265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-related educational program
Number of subjects: 80
Study 30132265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29762253 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT) for 60 min·d at 70% HRpeak
Number of subjects: 31
Study 29762253 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise training (INT) for 60 min·d (90% HRpeak for 3 min and 50% HRpeak for 3 min)
Number of subjects: 31
Study 29762253 — intervention group
Group type: COMPARATOR
Intervention: Both CONT and INT training
Number of subjects: 31
Study 26409098 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMRI pacemaker system
Number of subjects: 245
Study 25500229 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized high-frequency source ablation (HFSA)
Number of subjects: 232
Study 25500229 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (CPVI)
Number of subjects: 232
Study 25500229 — intervention group
Group type: COMPARATOR
Intervention: CPVI + HFSA
Number of subjects: 232
Study 25500229 — intervention group
Group type: EXPERIMENTAL
Intervention: HFSA
Number of subjects: 232
Study 22744994 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional PR plus harmonica playing (HT; n = 9)
Number of subjects: 28
Study 22744994 — intervention group
Group type: COMPARATOR
Intervention: Traditional PR (C; n = 16)
Number of subjects: 28
Study 22744994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample (both groups)
Number of subjects: 28
Study 20604702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling (TMC)
Number of subjects: 0
Study 20604702 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM)
Number of subjects: 0
Study 20604702 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 19030754 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 60
Study 19030754 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study 15515153 — intervention group
Group type: COMPARATOR
Intervention: Individual treatments compared to control
Number of subjects: 0
Study 12963896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with a topical retinoid (e.g., adapalene) and an antibiotic
Number of subjects: 0
Study 12963896 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoids alone
Number of subjects: 0
Study 12963896 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical or oral antibiotics
Number of subjects: 0
Study 10235199 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 2 x 10‐mg tablets 4 times daily
Number of subjects: 93
Study 10235199 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 1 x 10‐mg tablet + 1 placebo tablet 4 times daily
Number of subjects: 93
Study 9094866 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 177
Study 9094866 — intervention group
Group type: COMPARATOR
Intervention: Non-antibiotics
Number of subjects: 177
Study 9094866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactibilia
Number of subjects: 177
Study 9094866 — intervention group
Group type: COMPARATOR
Intervention: Sterile bile
Number of subjects: 177
Study 1811441 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved ORS formulation (maltodextrin 20 g, glycine 4 g, glycyl-glycine 4 g)
Number of subjects: 108
Study 1811441 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (WHO formulation containing citrate)
Number of subjects: 108
Study 1811441 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved ORS formulation
Number of subjects: 108
Study 31505228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Number of subjects: 260
Study 31505228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 30820060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SMX/TMP) 200/40 mg
Number of subjects: 0
Study 30820060 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole-trimethoprim (SMX/TMP) 400/80 mg
Number of subjects: 0
Study 28091858 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing dentures
Number of subjects: 30
Study 28091858 — intervention group
Group type: COMPARATOR
Intervention: Sleeping without dentures
Number of subjects: 30
Study 26545543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) at 65% of maximum aerobic capacity
Number of subjects: 30
Study 26545543 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) using 1 x 2 x 3 protocol at 65% of 1RM
Number of subjects: 30
Study 23321925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0
Study 21471414 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation with injection of calcium phosphate bone cement (Group 2)
Number of subjects: 48
Study 21471414 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plate fixation alone (Group 1)
Number of subjects: 48
Study 21471414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 19123930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (aerobic and strength exercises) twice a week under supervision of a physiotherapist
Number of subjects: 0
Study 19123930 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 19123930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 0
Study 17317762 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 767
Study 17317762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study 15750983 — intervention group
Group type: EXPERIMENTAL
Intervention: BD/middle‐flux polysulfone (PS)
Number of subjects: 138
Study 15750983 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF/high‐flux polysulfone (PS‐HDF)
Number of subjects: 138
Study 15750983 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate free biofiltration (AFB) with PAN
Number of subjects: 138
Study 15750983 — intervention group
Group type: COMPARATOR
Intervention: BD/cellulose acetate (AC)
Number of subjects: 138
Study 15750983 — intervention group
Group type: COMPARATOR
Intervention: BD/low‐flux polysulfone (PS)
Number of subjects: 138
Study 15750983 — intervention group
Group type: EXPERIMENTAL
Intervention: BD/middle‐flux PS or PA
Number of subjects: 138
Study 11599648 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly fluoxetine (90 mg/week)
Number of subjects: 117
Study 11599648 — intervention group
Group type: COMPARATOR
Intervention: Once-daily fluoxetine (20 mg/day)
Number of subjects: 117
Study 9040303 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 125 mg twice daily
Number of subjects: 375
Study 9040303 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 375
Study 9040303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 8187255 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 30 micrograms (0.6 ml) in 4.4 ml lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine
Number of subjects: 21
Study 8187255 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine carbonate 2% with 5 micrograms.ml‐1 epinephrine (Control Group)
Number of subjects: 21
Study 3367752 — intervention group
Group type: EXPERIMENTAL
Intervention: hand + ankle weights
Number of subjects: 8
Study 3367752 — intervention group
Group type: EXPERIMENTAL
Intervention: hand weights
Number of subjects: 8
Study 3367752 — intervention group
Group type: EXPERIMENTAL
Intervention: ankle weights
Number of subjects: 8
Study 3367752 — intervention group
Group type: COMPARATOR
Intervention: unloaded weights
Number of subjects: 8
Study 31530227 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) therapy (10 Hz, 600 pulses, 70% resting motor threshold amplitude)
Number of subjects: 20
Study 31530227 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) therapy
Number of subjects: 20
Study 31530227 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 31411696 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery
Number of subjects: 230
Study 31411696 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil
Number of subjects: 230
Study 31411696 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF)
Number of subjects: 230
Study 31411696 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 230
Study 27649982 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 (0.003%, 30 μg/mL) once daily for 28 days
Number of subjects: 123
Study 27649982 — intervention group
Group type: COMPARATOR
Intervention: Xalatan (0.005%, 50 μg/mL) once daily for 28 days
Number of subjects: 123
Study 27649982 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054
Number of subjects: 123
Study 25650049 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212
Number of subjects: 69
Study 25650049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24075603 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (ASE: 5-10mg twice-daily)
Number of subjects: 949
Study 24075603 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (OLA: 5-20mg once-daily)
Number of subjects: 949
Study 21729152 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV safety video on DVD
Number of subjects: 2345
Study 19208649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of unselected mononuclear cells (UNSEL)
Number of subjects: 200
Study 19208649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of selected CD34(+)CXCR4(+) cells (SEL)
Number of subjects: 200
Study 19208649 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL) without BM cell treatment
Number of subjects: 200
Study 19208649 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with BM cells with baseline LVEF < median (37%)
Number of subjects: 200
Study 19208649 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (UNSEL, SEL, CTRL)
Number of subjects: 200
Study 16672847 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection schedule with three waves and 6 days of measurement
Number of subjects: 360
Study 16672847 — intervention group
Group type: COMPARATOR
Intervention: Data collection schedule with one wave and Tuesday only
Number of subjects: 360
Study 15172712 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via the Ambu MediBag
Number of subjects: 100
Study 15172712 — intervention group
Group type: COMPARATOR
Intervention: 200 microg salbutamol via the Volumatic-Spacer
Number of subjects: 100
Study 10853626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (low dosages < or = 100 mg/day)
Number of subjects: 0
Study 10853626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (higher dosages)
Number of subjects: 0
Study 10853626 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 9104515 — intervention group
Group type: EXPERIMENTAL
Intervention: I:E ratio 1:1
Number of subjects: 9
Study 9104515 — intervention group
Group type: COMPARATOR
Intervention: I:E ratio 1:3
Number of subjects: 9
Study 8342505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 228
Study 8342505 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 228
Study 3572208 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg
Number of subjects: 27
Study 3572208 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 27